{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:40:18Z","timestamp":1792687218927,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jiph.2026.103387","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:10:38Z","timestamp":1792249838000},"page":"103387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omadacycline in the treatment of diverse bacterial infections: A retrospective analysis of clinical outcomes and adverse events"],"prefix":"10.1016","volume":"19","author":[{"given":"Wen-Jie","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hui","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-2450","authenticated-orcid":false,"given":"Jian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103387_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2026.103387_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/ciz394","article-title":"Omadacycline: a modernized tetracycline","volume":"69","author":"Gallagher","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2026.103387_bib4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14787210.2022.2021876","volume":"20","author":"Jean","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiph.2026.103387_bib5","article-title":"Omadacycline for peritoneal dialysis-associated peritonitis caused by Coxiella burnetii: a case report and literature review","volume":"13","author":"Hong","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jiph.2026.103387_bib6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s40121-026-01345-0","article-title":"Multicenter real-world outpatient use of intravenous omadacycline","volume":"15","author":"Van Anglen","year":"2026","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103387_bib7","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.2147\/IDR.S541192","article-title":"Clinical efficacy and safety of omadacycline versus tigecycline in treating severe pneumonia caused by carbapenem-resistant gram-negative bacilli: a retrospective cohort study","volume":"18","author":"Zhang","year":"2025","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2026.103387_bib8","article-title":"Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103387_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jiph.2026.103387_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02397-21","article-title":"Evaluation of the impact of comorbidities on omadacycline pharmacokinetics","volume":"67","author":"Trang","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103387_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103387_bib12","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s40121-024-01065-3","article-title":"Omadacycline for diverse infections in China: a real-world analysis of efficacy and safety","volume":"13","author":"Gao","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103387_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and european organization for research and treatment of cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiph.2026.103387_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106442","article-title":"Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial","volume":"184","author":"Pai","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.jiph.2026.103387_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106263","article-title":"Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment","volume":"57","author":"Cornely","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103387_bib17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-023-08815-7","article-title":"Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units","volume":"23","author":"Bai","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib18","article-title":"A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103387_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116711","article-title":"Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)","volume":"111","author":"Huband","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiph.2026.103387_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgar.2025.04.027","article-title":"vitro activity of omadacycline against bacterial isolates from bone\/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015-2023)","volume":"43","author":"Huband","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiph.2026.103387_bib22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s11739-021-02749-1","article-title":"Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections","volume":"16","author":"Matlock","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jiph.2026.103387_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12873-025-01177-0","article-title":"Empiric antibiotic therapy resistance and mortality in emergency department patients with bloodstream infection: a retrospective cohort study","volume":"25","author":"von Beck","year":"2025","journal-title":"BMC Emerg Med"},{"key":"10.1016\/j.jiph.2026.103387_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib25","article-title":"Advancements in the management of severe community-acquired pneumonia: a comprehensive narrative review","volume":"15","author":"Davis","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jiph.2026.103387_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0043-1778641","article-title":"Antibiotic strategies for severe community-acquired pneumonia","volume":"45","author":"Bassetti","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jiph.2026.103387_bib27","article-title":"Pharmacokinetics, safety and pharmacokinetics\/pharmacodynamics analysis of omadacycline in Chinese healthy subjects","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103387_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01080-23","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model","volume":"68","author":"Singh","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103387_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12866-025-03967-9","article-title":"In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study","volume":"25","author":"Lei","year":"2025","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jiph.2026.103387_bib30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jac\/dkaa558","article-title":"Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections","volume":"76","author":"Pai","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103387_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","article-title":"Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics","volume":"59","author":"Rodvold","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiph.2026.103387_bib32","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib33","article-title":"Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial","volume":"10","author":"Rodriguez","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jiph.2026.103387_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103387_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/biom14070783","article-title":"Third-generation tetracyclines: current knowledge and therapeutic potential","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jiph.2026.103387_bib36","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","article-title":"vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018","volume":"39","author":"Dong","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2026.103387_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-19","article-title":"Omadacycline efficacy against enterococcus faecalis isolated in China: in vitro activity, heteroresistance, and resistance mechanisms","volume":"64","author":"Lin","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:06:10Z","timestamp":1792685170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126002595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1876034126002595"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103387","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omadacycline in the treatment of diverse bacterial infections: A retrospective analysis of clinical outcomes and adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103387"}}